Who will benefit from the information gained from KINAXO Cellular Target Profiling® and KinAffinity®?
Selection of the most promising compounds to continue into advanced pre-clinical studies is one of the most challenging decisions facing directors of drug development programs. Multiple parameters must be considered in such decision-making, including not only the compound’s potency against primary target(s) but also potential off-target drug interactions. KINAXO’s services permit rational decisions based on unbiased, proteome-wide selectivity data, helping enormously in the development of drugs with well-characterized inhibition profiles.
